Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?

European journal of haematology - 1 Apr 2015

Mattioli Francesca, Puntoni Matteo, Marini Valeria, Fucile Carmen, Milano Giulia, Robbiano Luigi, Perrotta Silverio, Pinto Valeria, Martelli Antonietta, Forni Gian Luca

Abstract excerpt

OBJECTIVES: Bioavailability of deferasirox (DFX) is significantly affected by the timing of administration relative to times and to composition of meals. Its elimination half-life is also highly variable - in some patients as a result of gene polymorphisms. Understanding whether deferasirox plasm...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia
Share to Benzoates
Share to Chromatography, High Pressure Liquid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Iron Chelating Agents

Share to Pharmacogenetics

Share to Sex Factors

Share to Triazoles

Source

Identifiers

PMID: 25081908
DOI: 10.1111/ejh.12419

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25081908-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Determination of deferasirox plasma concentrations: do gender, physical and genetic differences affect chelation efficacy?PMID 25081908Read ↗

Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients.Semantic proximity Read ↗

Role of pharmacogenetics on deferasirox AUC and efficacy.Semantic proximity Read ↗

Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children.Semantic proximity Read ↗

Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.Semantic proximity Read ↗

Pharmacogenetic Study of Deferasirox, an Iron Chelating AgentSemantic proximity Read ↗

Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes.Semantic proximity Read ↗

Effect of Genetic Polymorphisms on the Pharmacokinetics of Deferasirox in Healthy Chinese Subjects and an Artificial Neural Networks Model for Pharmacokinetic Prediction.Semantic proximity Read ↗

Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients.Semantic proximity Read ↗

UGT1A6 genotype-related pharmacokinetics of deferiprone (L1) in healthy volunteers.Semantic proximity Read ↗

Impact of SNP Variants in PON-1 or UGT1A1 on Iron Chelation Therapy Outcomes and Zinc Status in Thalassemia Major Patients.Semantic proximity Read ↗

Three most common nonsynonymous UGT1A6*2 polymorphisms (Thr181Ala, Arg184Ser and Ser7Ala) and therapeutic response to deferiprone in β-thalassemia major patients.Semantic proximity Read ↗

Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.